PPAR-delta Inhibitors
2 drugsAbout PPAR-delta
PPAR-delta is a nuclear receptor protein regulating fatty acid metabolism, inflammation, and energy homeostasis. As a ligand-activated transcription factor, it influences genes involved in various physiological processes.
While PPAR-delta's involvement in metabolic pathways makes it a compelling drug target, there is currently no genetic evidence directly linking it to specific diseases.
PPAR-delta is targeted by one FDA-approved small molecule drug, IQIRVO (IPSEN), approved in 2024 and classified within the 'other' therapeutic area.
Top PPAR-delta Drugs
IPSEN is the only company with an approved drug targeting PPAR-delta.
Low market concentration suggests an opportunity for new entrants, but IPSEN's first-mover advantage creates a barrier.
PPAR-delta Drug Modality Landscape
Modalities
Routes of Administration
PPAR-delta is amenable to small molecule drugs, with oral options available for convenient dosing.
Explore alternative modalities like antibodies or peptides to differentiate from existing therapies.
PPAR-delta Clinical Trials 23 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on PPAR-delta. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 8 | 8 | 0 | 0 | 100% |
| Phase 2 | 8 | 1 | 4 | 3 | 20% |
| Phase 3 | 7 | 1 | 1 | 5 | 50% |
Top Sponsors
By Modality
Top Conditions
Phase 3 Readout Calendar Pro
2 Phase 3 trials testing approved PPAR-delta drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting PPAR-delta. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
PPAR-delta Drug Approval Timeline (2024 - 2024)
The first and only drug, IQIRVO, was approved in 2024.
Recent approval suggests growing interest, but saturation risk is low given the single approved drug.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 4 (3 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on PPAR-delta. A trial counts if an approved drug acting on PPAR-delta is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.